-
艾媒咨询|2024-2025年中国研学游经济市场运行监测报告
近年来,旅游市场强力复苏,居民出游意愿高涨。随着国民教育文化需求的提升、政府政策红利的释放以及家长教育观念的转变,研学游成为旅游市场重点发展方向。2023年中国研学游行业市场规模达1469亿元,预计2028年将突破3000亿元。中国研学游市场发展迅速,产业配套快速形成。产业链分布上,上游的资源提供方构成复杂,主体为高校、事业单位、研学基地和营地等。中游市场上,竞争格局较为分散,行业集中度较低,存在大量营收规模在千万元/人民币以下的中小机构。下游则对应用户层,如师生、学校、家长等。全球新经济产业第三方数据挖掘和分析机构iiMedia Research(艾媒咨询)最新发布的《2024-2025年中国研学游经济市场运行监测报告》数据显示,在研学游目的地的选择上,57.7%的消费者偏爱省内的短途旅行,单次1000-6000元的研学游产品成为超半数消费者的选择。随着研学游市场发展逐步成熟,同质化的研学旅行服务将越来越难以满足消费者需求。科技、制造、能源、互联网等跨领域的佼佼者也已进入这个庞大的市场,不断拓展行业边界,开发出丰富多样的跨界融合研学产品。相关企业需根据研学旅行未来趋势制定分众细化的特色研学项目应对市场挑战。
In recent years, the tourism market has seen a robust recovery, with a surge in residents' desire to travel. As the national demand for education and culture increases, along with the release of government policy dividends and the transformation of parents' educational concepts, study tours have become a key direction for the development of the tourism market. In 2023, the market size of China's study tour industry reached 146.9 billion yuan, and it is expected to exceed 300 billion yuan by 2028. The development of China's study tour market is rapid, with industry support quickly taking shape. In terms of the industry chain distribution, the upstream resource providers are complex, mainly consisting of universities, public institutions, study bases, and camps. In the midstream market, the competitive landscape is relatively fragmented, with a low industry concentration, and there are many small and medium-sized institutions with a revenue scale of less than 10 million yuan/RMB. The downstream corresponds to the user layer, such as teachers, students, schools, and parents. The latest "China Study Tour economic Market Operation Monitoring report from 2024 to 2025" released by iiMedia Research shows that in the choice of study tour destinations, 57.7% of consumers prefer short-distance travel within the province, and study tour products priced between 1000-6000 yuan per trip have become the choice of more than half of the consumers. As the study tour market gradually matures, homogenized study travel services will increasingly fail to meet consumer needs. Leaders in cross-disciplinary fields such as technology, manufacturing, energy, and the internet have also entered this vast market, continuously expanding industry boundaries and developing a rich and diverse range of cross-disciplinary integrated study products. Relevant companies need to formulate targeted study projects based on future trends in study travel to meet market challenges. -
艾媒咨询|2021年中国轻医美行业研究及产业链分析报告
本报告研究涉及企业/品牌/案例:爱美客,华熙生物,奇致激光,华韩整形,新氧,兰州生物
数据显示,2020年中国轻医美用户市场规模达到1520万人,预计到2021年将增至1813万人。在消费意识觉醒和消费需求驱动下,机构、医生在供给端强势助推轻医美行业更快速发展,预计2021年中国轻医美市场将达到798亿元,同比增长46.4%。在行业快速增长的同时,轻医美产业链各环节企业由于集中度不同导致利润分配不均,具体来看,上游原料耗材企业由于高技术壁垒,市场集中度较高,毛利率高于中下游企业,如知名玻尿酸、肉毒素产品制造企业爱美客、华熙生物等,而中下游由于竞争分散,单体获利参差不齐,更容易产生乱象。但总体来说,在行业监管加强、机构自律、平台监督等多方力量共同作用下,轻医美行业将会向线上化、品牌化、规范化发展。
According to the data, the market size of China's light medical beauty users will reach 15.2 million in 2020, and it is expected to increase to 18.13 million by 2021. Driven by the awakening of consumer awareness and consumer demand, institutions and doctors strongly boost the rapid development of light medical beauty industry in the supply side. It is estimated that China's light medical beauty market will reach 79.8 billion yuan in 2021, with a year-on-year growth of 46.4%. With the rapid growth of the industry, the profit distribution of enterprises in each link of the light medical beauty industry chain is uneven due to different concentration. Specifically, due to high technical barriers, the upstream raw materials and consumables enterprises have higher market concentration and higher gross profit rate than the middle and downstream enterprises, such as the well-known hyaluronic acid, botulinum toxin product manufacturing enterprises aimekke, Huaxi biology, etc., while the middle and downstream enterprises have higher gross profit rate due to scattered competition, Individual profit is uneven, more likely to produce chaos. But on the whole, under the joint action of industry supervision, institutional self-discipline, platform supervision and other forces, the light medical beauty industry will develop to online, brand and standardization. -
艾媒咨询|2020年中国细胞生物产业和商业应用分析报告
本报告研究涉及企业/品牌/案例:华夏源、复星医药。
中国细胞生物产业类型呈现多样化趋势,细胞生物临床研究不断深化,伴随生态合作的拓展将进一步加速细胞生物产业生态圈的形成,生态圈的完善将在很大限度上推动产业快速发展。数据显示,中国细胞治疗企业融资金额不断增加,从2014年的0.2亿元增长至2019年的28.9亿元。其中,2018年中国细胞治疗企业融资额同比增长706.8%,呈现迅猛发展态势。未来中国细胞生物产业的发展将充满机遇,同时也有挑战并存。后续产业的发展,将在5G、人工智能等新技术应用下加速升级。面临多端变化的市场格局,企业也应积极开展生态合作以及更为密切关注市场需求动向,将疗法和新一代医疗创新技术深度融合,实现市场产品多元化与差异化,并推出独特性的精准治疗,从而最大限度地释放产业价值。
The types of cell biological industry in China show a trend of diversification, and the deepening of cell biological clinical research will further accelerate the formation of the cell biological industry ecosystem with the expansion of ecological cooperation, and the improvement of the ecosystem will promote the rapid development of the industry to a large extent. Data show that the financing amount of Chinese cell therapy enterprises keeps increasing, from 20 million yuan in 2014 to 2.89 billion yuan in 2019. Among them, in 2018, the financing amount of Chinese cell therapy enterprises increased by 706.8% year on year, showing a rapid development trend. In the future, the development of China's cell biology industry will be full of opportunities and challenges. The development of subsequent industries will be accelerated with the application of new technologies such as 5G and ARTIFICIAL intelligence. In the face of the changing market pattern, enterprises should also actively carry out ecological cooperation and pay close attention to the trend of market demand, deeply integrate therapy and new-generation medical innovation technology, realize the diversification and differentiation of market products, and launch unique precision therapy, so as to maximize the release of industrial value. -
艾媒咨询|2020H1中国直播电商行业主播职业发展现状及趋势研究报告
本报告研究涉及企业/品牌/案例:谦寻文化,青藤文化,Drama TV。
其他提及企业/品牌:淘宝,抖音,快手,京东,亚马逊,YouTube,Instagram,Facebook,美ONE,蚊子会,无忧传媒,薇龙文化,美腕,蜂群文化,风马牛传媒,妃鱼,至尊宝物,101名师工厂,泰洋川禾,特抱抱,歪研会,言止传媒,无锋科技,构美,梨视频,快买他,迈吉客科技等。
2020年5月27日,全球知名的新经济产业第三方数据挖掘和分析机构iiMedia Research(艾媒咨询) 发布《2020H1中国直播电商行业主播职业发展现状及趋势研究报告》。报告根据艾媒数据中心、艾媒咨询商业情报数据库、艾媒商情舆情数据监测系统基础数据,对在直播电商行业的主播情况进行深度分析,剖析主播薪酬、主播能力、主播与MCN机构博弈等的关键信息,总结当前的主播发展业态并且预判2020-2021年中国直播电商行业主播职业发展趋势及风险。艾媒咨询分析师认为,“门槛低”“薪资高”“需求大”,电商直播行业持续吸引大量人才加入赛道,带货主播行业竞争激烈。但商家或者MCN机构主要通过隐性能力严格筛选综合能力强的高效性人才,因而并非所有网红都能胜任。
During the outbreak, the mainity industry generated a large recruitment demand. But from the professional structure, waist anchors occupy the majority, they grew up on a meagre base salary to live and red slow, psychological pressure. Moreover, the main broadcaster generally faces no traffic, traffic but no sales, sales but not money and other difficulties, the need for relevant government departments to issue a certain industry norms to promote the long-term professional development of the industry. -
艾媒研报|2019小米集团运行状况及行业趋势研究报告
本报告研究涉及企业/品牌/案例:小米集团,顺为资本,晨兴资本,IDG资本,启明创投,高通创投,淡马锡,DST Global,厚朴投资,云锋基金,All-Stars ,GIC,百度,海尔,华为,京东,谷歌,科大讯飞,中兴,中国移动,中国电信,中国联通,创维,水晶光电
5G技术的加速落地推动着中国智能手机行业与AIoT行业的变革与发展。iiMedia Research (艾媒咨询)数据显示,2019年上半年国内手机市场总体出货量1.86亿部,同比下降5.1%, 4G手机出货量为1.78 亿部,同比下降 4.2%。与此同时,中国5G手机新机型加速上市,新一轮换机潮前奏已经开始,手机行业面临洗牌。AIoT领域,iiMedia Research (艾媒咨询)数据显示,2018年中国AIoT智能硬件市场规模达5000亿元,呈高速增长态势,预计2020年将突破10000亿元。2019年小米集团制定了“手机+AIoT”的双引擎战略,虽然小米在5G手机以及AIoT领域已经取得一定成绩,但面对巨头环伺的激烈竞争环境,小米未来的发展道路仍充满挑战,核心技术壁垒有待进一步提升。
The accelerated implementation of 5G technology promotes the reform and development of China's smart phone industry and AIoT industry. According to the data of iimedia research, in the first half of 2019, the total shipment volume of domestic mobile phone market was 186 million, down 5.1% year-on-year, and the 4G mobile phone shipment volume was 178 million, down 4.2% year-on-year. At the same time, Chinese mobile phone manufacturers are speeding up 5G mobile phones, and a new round of mobile phones has begun. The mobile phone industry is facing a reshuffle. In the field of AIoT, according to the data of iimedia research, in 2018, the scale of China's AIoT intelligent hardware market reached 500 billion yuan, showing a high-speed growth trend, and is expected to exceed 1 billion yuan in 2020. In 2019, Xiaomi group formulated the dual engine strategy of “mobile phone + AIoT “. Although Xiaomi has made some achievements in 5G mobile phone and AIoT, in the face of the fierce competition environment surrounded by giants, Xiaomi's future development path is still full of challenges, and the core technical barriers need to be further improved. -
艾媒报告 |2019全球智能终端生态与华为鸿蒙系统市场机会调查报告
本报告研究涉及企业/品牌/案例:华为,谷歌,小米,vivo,oppo,三星
2019年5月21日,华为宣布其自主研发的操作系统“华为鸿蒙”最快2019年秋季面市,随即引发社会广泛关注。数据显示,在全球智能手机市场萎缩的大背景下,华为市场份额在2019第一季度跃升至全球智能手机市场份额第二位。此次研发操作系统或与中美贸易战直接相关。美方对多家中国科技企业实施制裁使得中国科技企业加快技术自立步伐。对于华为自研鸿蒙操作系统的态度,近九成中国企业认为自研操作系统是必要的,超九成网民和企业支持华为开发自身的操作系统。艾媒咨询分析师认为,自研系统开发的关键在于解决生态建设问题。在贸易战背景下,加强核心技术研发具有必要性。在5G技术趋于成熟之时推出新的操作系统,对于华为而言也是发展良机。
On May 21, 2019, Huawei announced that its independently-developed operating system ““Huawei Hongmeng““ would be available in the fall of 2019 at the earliest, which immediately attracted wide attention from the public. in the context of the shrinking global smartphone market, Huawei's market share jumped to the second place in the global smartphone market in the first quarter of 2019. The development of the operating system may be directly related to the trade war between China and the United States. US sanctions on a number of Chinese technology companies have accelerated the pace of their technological self-reliance. As for Huawei's self-developed Hongmeng operating system, nearly 90% of Chinese enterprises believe that self-developed operating system is necessary, and more than 90% of Internet users and enterprises support Huawei to develop its own operating system. Analysts in iiMedia believe that the key to the development of self-research system is to solve the problem of ecological construction. Against the background of trade war, it is necessary to strengthen the research and development of core technologies. Launching a new operating system at a time when 5G technology is maturing is also a good development opportunity for Huawei. -
艾媒报告 |2019中国基因测序产业研究和商业应用分析报告
本报告研究涉及企业/品牌/案例:Thermo Fisher(美),Illuminate(美),(瑞士),Stem cells(加),R&D(瑞士),华大基因,贝瑞基因,金城检验,美吉生物,恒创基因,基研生物,谱元科技,景杰生物,燃石生物,基迪奥生物,谷和信息,圣庭生物,天昊生物,诺禾致源,百迈克生物,思博奥科,赛莱拉,赛贝、北昊干细胞,达安基因,燃石医学、泛生子基因、世和基因,臻和生物,鹍远基因,23魔方,瀚海基因,百奥赛图,克睿基因,药明明码,裕策生物
随着基因测序的技术推进,基因测序开始应用于生物、侦查、无创产前检测和肿瘤治疗等场景中。技术的市场化应用吸引了全球资本方关注,iiMedia Research(艾媒咨询)数据显示,2018年全球医疗健康领域资本市场中,生物技术领域获得309件投资案共138亿元美元,领跑所有细分领域。中国生物技术科研研发实力厚积薄发,特别是科创板推动了基因测序市场的进一步升温,越来越多的生物创业公司在创业初期已获得高额融资。目前,中国已经基本形成了完整的上中下游产业链,但除了华大基因、贝瑞基因等少数头部企业,中国基因测序企业多数分布于产业链中下游,并且开始出现产品同质化等问题。艾媒咨询分析师认为,第二代测序技术的普及以及第三代测序技术的加紧研发将使得基因测序作为一个更加普遍的技术手段应用到不同场景之中,但目前仍然存在监管体系不够完善、道德伦理风险等问题。企业方面应当专注研究核心技术专利,通过人才储备和差异化竞争获得市场优势;行业和相关部门应当尽快完善行业规范管理体系,推动产业健康发展。
With the advancement of gene sequencing technology, gene sequencing began to be used in biological, detection, noninvasive prenatal testing and tumor treatment and other scenarios. The market-oriented application of technology has attracted global capital attention, with iiMedia Research leading all segments of the world in 309 investments in the global healthcare capital markets in 2018, with 309 investments, according to iiMedia Research. China's biotechnology research and development strength thick and thin hair, especially the science and technology board to promote the gene sequencing market further heating up, more and more bio-startup companies in the early stage of the start-up has been high financing. At present, China has basically formed a complete upstream and downstream industrial chain, but in addition to Huada gene, Berry gene and a few other head enterprises, Most of China's gene sequencing enterprises are distributed in the middle and lower reaches of the industrial chain, and began to appear product homogenization and other issues. Ai media consulting analysts believe that the popularity of second-generation sequencing technology and the third generation of sequencing technology will make gene sequencing as a more common technical means to apply to different scenarios, but there are still problems such as inadequate regulatory system, ethical risks. Enterprises should focus on researching core technology patents and gain market advantages through talent pool and differentiated competition, and industries and related departments should improve the industry standard management system as soon as possible to promote the healthy development of the industry. -
艾媒报告 |2019年中国生物医药产业发展及舆论焦点分析报告
本报告研究涉及企业/品牌包括:Takeda、GSK、Sanofi、Celgene、Novartis、宝洁、CVC Fund VII、Shire、诺华OTC、Bioverativ、Juno Therapeutics、AveXis、Impact Biomedicines、Tesaro、Ablynx、默克OTC、Recordati控股公司FIMEI、复星医药、海正药业、康弘药业、泰合健康、齐鲁制药、复宏汉霖、信达生物、张江生物、恒瑞医药、三生国健、嘉和生物、百奥泰、深圳龙瑞、天坛生物、华兰生物、博雅生物、上海莱士、卫光生物、辽宁成大、智飞生物、康泰生物、沃森生物、利德曼、交大昂立、华润双鹤、力生制药、海欣股份、联环药业、白云山、中源协和、普洛药业
随着生物医药技术不断突破,中国生物医药产业快速发展,2018年,单抗、血液制品、疫苗等生物医药相关领域多家头部上市企业营收均超亿元,实现同比增长。iiMedia Research(艾媒咨询)监测发现,生物医药产业网络言值指数为49.7,网民评价态度偏向正面,上海网民对生物医药产业的关注度最高。未来,随着中国生物医药行业上市公司数量增多,行业与企业间竞争将更加激烈。
The scale of China's bio-pharmaceutical industry continues to grow, and the proportion of bio-pharmaceutical output in the pharmaceutical industry continues to rise. In 2017, the total output value of the bio-pharmaceutical industry in China's park was about 1.5 trillion yuan. At present, China's biomedical industry has formed three major clusters, including the Bohai Rim region, the Yangtze River Delta region and the Pearl River Delta region, and the industrial agglomeration effect is outstanding. China's bio-pharmaceutical industry is in a stage of rapid development. In 2018, many head-to-head listed companies in biomedical related fields such as monoclonal antibodies, blood products and vaccines all exceeded 100 million yuan, achieving year-on-year growth. According to iiMedia Research, netizens in Shanghai are most concerned about the biomedical industry, and 40.9% of netizens surveyed support the application of transgenic technology in the pharmaceutical field. Among the heads of monoclonal antibodies, blood products and vaccines, Fuhong Hanlin as well as Weiguang Bio and Lidmanthe has the best online reputation,iiMedia Consulting analysts believe that in the future, the combination of artificial intelligence with new drug research and the fierce competition among head enterprises is an important trend in the development of China's biomedical industry.
没找到想要的报告?
扫码添加客服参与预约/定制,第一时间获取行业推荐报告!
智库热榜
艾媒咨询|2024-2025年中国银发经济投资前景分析报告
艾媒咨询|2024-2025年中国烘焙食品行业现状及趋势研究报告
艾媒咨询 | 2023-2024年中国休闲食品产业现状及消费行为数据研究报告
艾媒咨询|2024-2025年全球及中国新能源汽车行业消费趋势监测与案例研究报告
艾媒咨询 | 2023-2024年中国全域旅游产业运行数据及发展趋势研究报告
艾媒咨询 | 2024年中国家用美容仪行业消费者洞察研究报告
艾媒咨询|赵一鸣零食店消费行为洞察及行业趋势报告(2024)
艾媒咨询|2024年中国月饼行业创新发展研究报告
艾媒咨询 | 2024年中国数字中台市场研究报告
艾媒咨询|2023-2024年全球及中国跨境电商运营数据及典型企业分析研究报告
艾媒咨询|2024年中国家清产品消费趋势洞察报告